Management of Major Bleeding Events in Patients Treated With Rivaroxaban Versus Warfarin: Results From the ROCKET AF Trial

被引：0
|
作者：
Piccini, Jonathan P. [1 ]
Garg, Jyotsna [2 ]
Patel, Manesh R. [1 ]
Lokhnygina, Yuliya [3 ]
Goodman, Shaun G. [4 ,5 ]
Becker, Richard C. [1 ]
Berkowitz, Scott D. [6 ]
Breithardt, Gunter [7 ]
Hacke, Werner [8 ]
Halperin, Jonathan L. [9 ]
Hankey, Graeme I. [10 ,11 ]
Nessel, Christopher C. [12 ]
Mahaffey, Kenneth W. [1 ]
Singer, Daniel E. [13 ,14 ]
Califf, Robert M. [15 ]
Fox, Keith A. [16 ,17 ]
机构：
[1] Duke Clin Rsch Inst, Dept Med, Div Cardiol, Durham, NC USA
[2] Duke Clin Rsch Inst, Stat Grp, Durham, NC USA
[3] Duke Clin Rsch Inst, Dept Biostat & Bioinformat, Durham, NC USA
[4] Univ Toronto, St Michaels Hosp, Canadian Heart Rsch Cntr, Toronto, ON, Canada
[5] Terrence Donnelly Heart Cntr, Toronto, ON, Canada
[6] Bayer HealthCare Pharmaceut, Global Therapeut Rsch, Cardiovasc Pharmacol, Montville, NJ USA
[7] Hosp Univ Munster, Dept Cardiol & Angiol, Munster, Germany
[8] Heidelberg Univ, Dept Neurol, Heidelberg, Germany
[9] Mt Sinai, Icahn Sch Med, Mt Sinai Med Cntr, Cardiovasc Inst, New York, NY USA
[10] Univ Western Australia, Sch Med & Pharmacol, Dept Neurol, Perth, WA 6009, Australia
[11] Royal Perth Hosp, Stroke Unit, Perth, WA 6001, Australia
[12] Janssen Rsch & Dev, Clin Rsch, Raritan, NJ USA
[13] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[14] Harvard Univ, Sch Med, Boston, MA USA
[15] Duke Translat Med Inst, Dept Med, Div Cardiol, Durham, NC USA
[16] Univ Edinburgh, Cntr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
[17] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland
来源：
CIRCULATION | 2013年 / 128卷 / 22期
关键词：
Atrial fibrillation; Stroke; Risk factors;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15879
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence
    Weir, Matthew R.
    Berger, Jeffrey S.
    Ashton, Veronica
    Laliberte, Francois
    Brown, Kip
    Lefebvre, Patrick
    Schein, Jeffrey
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (10) : 1891 - 1900
  • [42] Selective Serotonin Reuptake Inhibitors Increase Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial
    Quinn, Gene R.
    Hellkamp, Anne S.
    Becker, Richard C.
    Berkowitz, Scott D.
    Breithardt, Guenter
    Fox, Keith A.
    Hacke, Werner
    Halperin, Jonathan L.
    Hankey, Graeme J.
    Mahaffey, Kenneth W.
    Nessel, Christopher C.
    Patel, Manesh R.
    Piccini, Jonathan P.
    Singer, Daniel E.
    CIRCULATION, 2016, 134
  • [43] Selective Serotonin Reuptake Inhibitors Increase Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial
    Quinn, Gene R.
    Hellkamp, Anne S.
    Becker, Richard C.
    Berkowitz, Scott D.
    Breithardt, Guenter
    Fox, Keith A.
    Hacke, Werner
    Halperin, Jonathan L.
    Hankey, Graeme J.
    Mahaffey, Kenneth W.
    Nessel, Christopher C.
    Patel, Manesh R.
    Piccini, Jonathan P.
    Singer, Daniel E.
    CIRCULATION, 2016, 134
  • [44] Major bleeding in patients with atrial fibrillation treated with apixaban versus warfarin in combination with amiodarone: nationwide cohort study
    Hansson, Astrid Fritz
    Modica, Angelo
    Renlund, Henrik
    Christersson, Christina
    Held, Claes
    Batra, Gorav
    OPEN HEART, 2024, 11 (01):
  • [45] Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation
    Adeboyeje, Gboyega
    Sylwestrzak, Gosia
    Barron, John J.
    White, Jeff
    Rosenberg, Alan
    Abarca, Jacob
    Crawford, Geoffrey
    Redberg, Rita
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (09) : 968 - 978
  • [46] Genetic Risk Factors for Major Bleeding in Patients Treated With Warfarin in a Community Setting
    Roth, J. A.
    Boudreau, D.
    Fujii, M. M.
    Farin, F. M.
    Rettie, A. E.
    Thummel, K. E.
    Veenstra, D. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (06) : 636 - 643
  • [47] Assessing the management of major bleeding events in patients treated by direct oral anticoagulant in an emergency department
    Durand, Julien
    Parat, Stephanie
    Lega, Jean-Christophe
    Dargaud, Yessim
    Potinet, Veronique
    Jacquin, Laurent
    Tazarourte, Karim
    Douplat, Marion
    ANNALES DE BIOLOGIE CLINIQUE, 2021, 79 (04) : 315 - 324
  • [48] Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
    Bahit, M. Cecilia
    Lopes, Renato D.
    Wojdyla, Daniel M.
    Held, Claes
    Hanna, Michael
    Vinereanu, Dragos
    Hylek, Elaine M.
    Verheugt, Freek
    Goto, Shinya
    Alexander, John H.
    Wallentin, Lars
    Granger, Christopher B.
    HEART, 2017, 103 (08) : 623 - 628
  • [49] Rivaroxaban vs. Warfarin in Japanese Patients With Non-Valvular Atrial Fibrillation in Relation to Age - Insight From J-ROCKET AF
    Hori, Masatsugu
    Matsumoto, Masayasu
    Tanahashi, Norio
    Momomura, Shin-ichi
    Uchiyama, Shinichiro
    Goto, Shinya
    Izumi, Tohru
    Koretsune, Yukihiro
    Kajikawa, Mariko
    Kato, Masaharu
    Ueda, Hitoshi
    Iekushi, Kazuma
    Yamanaka, Satoshi
    Tajiri, Masahiro
    CIRCULATION JOURNAL, 2014, 78 (06) : 1349 - U260
  • [50] Comparison of Events Across Definitions of Major Bleeding in the Engage AF-TIMI 48 Trial
    Bergmark, Brian A.
    Stehouwer, Alexander
    Wiviott, Stephen D.
    Ruff, Christian T.
    Antman, Elliott M.
    Nordio, Francesco
    Kuder, Julia F.
    Kamphuisen, Pieter W.
    Mercuri, Michele F.
    Lanz, Hanz
    Braunwald, Eugene
    Giugliano, Robert P.
    CIRCULATION, 2017, 136
12345